Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Up 14.7% in April

Sensus Healthcare, Inc. (NASDAQ:SRTS) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 422,044 shares, an increase of 14.7% from the March 31st total of 368,090 shares. Based on an average daily trading volume, of 36,932 shares, the short-interest ratio is currently 11.4 days. Currently, 2.8% of the shares of the company are short sold.

Institutional Trading of Sensus Healthcare

Several hedge funds have recently added to or reduced their stakes in SRTS. Geode Capital Management LLC lifted its holdings in Sensus Healthcare by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after purchasing an additional 3,766 shares during the last quarter. Sachetta LLC lifted its holdings in Sensus Healthcare by 8.0% during the 3rd quarter. Sachetta LLC now owns 139,008 shares of the company’s stock worth $436,000 after purchasing an additional 10,333 shares during the last quarter. Pacific Ridge Capital Partners LLC lifted its holdings in Sensus Healthcare by 26.1% during the 3rd quarter. Pacific Ridge Capital Partners LLC now owns 573,389 shares of the company’s stock worth $1,800,000 after purchasing an additional 118,628 shares during the last quarter. Divisadero Street Capital Management LP lifted its holdings in Sensus Healthcare by 39.5% during the 3rd quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock worth $1,422,000 after purchasing an additional 128,224 shares during the last quarter. Finally, Mindset Wealth Management LLC lifted its holdings in Sensus Healthcare by 28.1% during the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after purchasing an additional 11,000 shares during the last quarter. 25.30% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Trading Up 1.8%

NASDAQ:SRTS opened at $3.97 on Friday. The stock has a market cap of $65.35 million, a P/E ratio of -8.45 and a beta of 1.28. The stock has a 50 day simple moving average of $4.13 and a 200 day simple moving average of $4.13. Sensus Healthcare has a 1-year low of $3.03 and a 1-year high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.10). The firm had revenue of $4.94 million for the quarter, compared to analyst estimates of $8.35 million. Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Alliance Global Partners assumed coverage on Sensus Healthcare in a research report on Friday, March 6th. They issued a “buy” rating and a $7.50 price objective for the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st. Maxim Group cut their price objective on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Finally, Wall Street Zen cut Sensus Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Sensus Healthcare has a consensus rating of “Moderate Buy” and an average price target of $6.88.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.